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Abstract The aim of the presented work is the comparison of aqueous and 1-octanol
solubilities of different acyclovir derivatives and their hydroxypropyl-b-cyclodextrin
inclusion complexes. The solubility measurements were carried out at different tempera-
tures over the range 25–45 C using water, 1-octanol, water saturated with 1-octanol,
1-octanol saturated with water, buffered aqueous solutions (pH = 5.5 and 7.0) and buf-
fered aqueous solutions containing cyclodextrin as solvents. The aqueous solubilities of the
compounds are very low but may be enhanced by complexation with hydroxypropyl-b-
cyclodextrin, especially if the acyclovir derivatives have aromatic groups which may be
included in the cyclodextrin cavity. The values of 1-octanol–water partition coefficients of
acyclovir derivatives, obtained using extraction experiments, showed a similar sequence as
the solubility results in 1-octanol. Additionally, some molecular mechanics and molecular
dynamic calculations were performed to determine optimized structures of acyclovir
derivative complexes with b-cyclodextrin treated as a model.
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1 Introduction
Herpes viruses are the most wide-spread DNA human viruses, so searching for new effi-
cient drugs possessing good antiviral activity is very important. The antiviral drugs have
been used from 1960s, but new drugs with higher bioactivity and lower toxicity are
continually being developed and tested. The first antiviral drugs: synthetic analogs of
pyrimidine–idoxyuridine, trifluridine and vidarabine, were synthesized in 1960 [1]. They
have low bioactivity and high toxicity, so now are used only to cure eye infections.
Acyclovir, 1, which is a substituted guanine, belongs to the next generation of antiviral
drugs. This drug, synthesized in 1977 by Ellion and coworkers [2], was registered in 1982
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and now is a well known, selective, antiviral agent [1]. The toxicity of acyclovir is lower
than other antiviral dugs, due to its acyclic sugar chain. Acyclovir, after phosphorylation of
the sugar chain, which takes place in infected cells, can inhibit replication of viruses HSV-
1 and HSV-2. Several derivatives of acyclovir, obtained by modification of acyclic chain,
have been synthesized and registered as drugs [1, 3]. The mechanism of their antiviral
action is similar to that of acyclovir. Other examples of acyclovir derivatives registered as
antiviral drugs are prodrugs, which are bioactive only after disintegration to acyclovir in
the human body. Application of antiviral drugs as acyclovir prodrugs, like valacyclovir or
famciclovir, gives the possibility of enhancing the absorption of acyclovir in the human
body. In the case of application of valacyclovir, absorption is four times higher than by
application of acyclovir [1].
Some guanine substituted acyclovir derivatives were synthesized by De Clerq and
coworkers [4, 5]. Those derivatives have somewhat greater antiviral activity towards HSV
viruses than the parent drug. Tricyclic acyclovir derivatives synthesized by Golankiewicz
and coworkers have high antiviral activity and good fluorescent properties, important for
monitoring their concentration in body fluids. Their synthesis, structures, antiviral and
spectral properties have been the subject of many publications [6–14]. The bioactivity and
spectral properties of tricyclic acyclovir derivatives were summarized by Golankiewicz
and Ostrowski in a mini review [15]; they found that, generally, substitution in appended
rings enhanced the antiviral properties and selectivity of the studied compounds. The
magnitude of antiviral activity towards different viruses depends on the type, position of
substituted group and the kind of acyclic sugar chain. In particular, substitution in the
6th position by a phenyl or 4-biphenylyl group afforded the greatest increase in antiviral
activity [15]. Compound 11 (6-Ph-O-Me-TACV) (Fig. 1) shows 2–7 times higher
antiherpetic activity towards HSV-1 and HSV-2 viruses than the parent acyclovir
when comparing the concentrations required to reduce virus-induced cytopathicity by
50 % [8].
In our earlier work [16] we determined aqueous and 1-octanol solubility and partition
coefficient between these two solvents of acyclovir and chosen acyclovir derivatives.
Structures of those compounds are shown in Fig. 1. The work showed extremely low
aqueous solubilities (10-3 to 10-5 moldm-3) for the main group of these compounds,
especially with aromatic substituents. Other thermodynamic properties of these compounds
in aqueous solutions, e.g. partial molar volumes and heat capacities, were determined by
Zielenkiewicz and coworkers [17, 18]. The low aqueous solubility of tricyclic acyclovir
derivatives is disadvantageous for drug application and absorption by cells, so enhance-
ment of their solubility seems to be very important. One of the ways of enhancing solu-
bility of tricyclic analogs of acyclovir in aqueous solutions can be the formation of
inclusion complexes with cyclodextrins. Natural and substituted cyclodextrins are known
as solubilizing agents for many drugs used in pharmacy, acting by forming inclusion and
non-inclusion complexes with them [19]. Native and substituted cyclodextrins are gener-
ally nontoxic and may be used in pharmacy, mainly as solubilizers, but sometimes as
stabilizers or in order to enhance bioactivity or reduce local drug irritation [18]. Hydro-
xypropyl-derivatives of a-, b-, and c-cyclodextrins are especially suitable for drug for-
mulation due to their amorphous form in the solid state. Now, worldwide more than
40 different drugs are marketed in the form of native and substituted cyclodextrin
complexes.
Our study on complexation of chosen tricyclic acyclovir derivatives in aqueous buffered
solutions indicates significant enhancement of solubility of the studied compounds,
especially these possessing aromatic substituents [20]. The increase of solubility is mainly
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caused by inclusion of hydrophobic groups inside the cyclodextrin cavity. The complex-
ation of alkyl and aromatic parts of tricyclic acyclovir derivatives in cyclodextrin cavities
was confirmed by 1H NMR. Differential scanning calorimetry (DSC) experiments
also indicate the existence of cyclodextrin complexes with studied compounds in the solid
state [19].
In the literature, there are only a few reports of acyclovir and their derivatives com-
plexed with cyclodextrins [21–26]. Stability constants of these complexes and the
enhancement of aqueous solubility are low, but results of in vitro experiments indicated
that stability, absorption and permeation of drugs used as cyclodextrin complexes are
higher than those of the pure drugs [25, 26].
The aim of our work is the comparison of aqueous and 1-octanol solubilities of tricyclic
acyclovir derivatives possessing high antiviral activity and their cyclodextrin complexes,
and connecting these results with the values of their partition coefficients between water
and 1-octanol determined by extraction experiments. Additionally, molecular modeling
and molecular dynamic optimizations of cyclodextrin inclusion complexes with tricyclic
acyclovir analogs were performed in order to explain structures and the physicochemical
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Fig. 1 Structures of acyclovir and its derivatives which are the subject of this work




The following compounds (1–12) synthesized by Golankiewicz and coworkers [6–15] were
investigated in our work: 1, acyclovir, 9-[(2-hydroxyethoxy)methyl] guanine (ACV); 2,
8-bromo-9-[(2-hydroxyethoxy)methyl] guanine (8-Br-ACV); 3, ganciclovir, 9-[(1,3-dihy-
droxy-2-propoxy)methyl]guanine (GCV); 4, 3,9-dihydro-3-[(2-hydroxyethoxy)methyl]-9-
oxo-5H-imidazol[1,2-a]purine (TACV); and its substituted derivatives; 5, 6-methyl (6-Me-
TACV); 6, 2-bromo-6-methyl (2-Br-6-Me-TACV); 7, 6-tert-butyl (6-t-But-TACV); 8,
6-phenyl (6-Ph-TACV); 9, 6-(4-biphenylyl) (6-Ph-Ph-TACV); 10, 6-(4-bromophenyl) (6-
Br-Ph-TACV); 11, 6-(2-naphthyl) (6-napht)-TACV]; 12, 6-(4-methoxyphenyl), (6-Me-O-
Ph-TACV).
The structures of these compounds are given in Fig. 1. All of the compounds were
freshly prepared for these studies. They were purified by recrystallization and the resulting
compounds were homogenous according to HPLC and 1H NMR analysis.
The hydroxypropyl-b-cyclodextrin (HP-b-CD) was purchased from Janssen Drug
Delivery System (USA), R81216 no 30 221 54, and used without additional purification.
KH2PO4 and Na2HPO4 salts used for preparation of buffer solutions were of analytical
grade (POCh, Gliwice, Poland). Distilled and deionized water from a Milli-Q system
(Millipore, USA) was used for solution preparation.
2.2 Solubility Experiments
2.2.1 Determination of Solubility in Water or 1-Octanol
Saturated solutions of compounds 1–12 were obtained in a thermostated apparatus holding
glass ampoules of 15 cm3 volume, which could be rotated by 180. The sample of sub-
stance examined (10 mg or 80 mg for 6-Me-TACV) was placed in a glass ampoule and
double-distilled, deionized water (Millipore, Elix 5 purifier), or pure anhydrous 1-octanol
(Sigma 99 %) was added. To attain thermodynamic equilibrium, the solute and the solvent
were mixed continuously for a minimum of 4 days at a speed of 25 rpm. After the
experiment was completed, the sample was centrifuged at 40,000 rpm for 40 min at
25 ± 0.1 C, the supernatant liquid was collected, diluted, and its concentration deter-
mined with a UV–Vis (Varian Carry IE) spectrophotometer. The experiments were repe-
ated at least three times for each solubility.
2.2.2 Determination of Solubility in Buffered Cyclodextrin Solutions
Solubilities of the studied compounds was ensured according to the excess method of
Higuchi and Connors [30]. Compounds 4–9 and 11–12 were chosen for these studies,
because their aqueous solubility is very low and should be enhanced for pharmaceutical
applications. Additionally, their structures suggested that these compounds may be come
complexed by cyclodextrins, especially tricyclic acyclovir derivatives possessing aromatic
substituents. An excess amount of compounds 4–9 and 11–12 was added to 1.5 mL of
aqueous phosphate buffer (concentration of buffer was equal 0.067 moldm-3) solutions,
(pH = 5.5 or 7.0) containing various concentration of HP-b-CD. The cyclodextrin con-
centration changed in the range of 10-3 to 2 9 10-2 moldm-3. The suspensions were
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shaken in screw-capped plastic vials in a water bath thermostat with the volume of 60 dm3
(home made apparatus by IChF PAN) at 25 and 37 C. After 7 days equilibrium was
reached and then the suspensions were centrifuged and the absorbance of the studied
compounds was measured by UV–Vis spectrophotometry using a Shimadzu UV 2401 PC
Spectrometer equipped with a thermostatically controlled cell compartment. During the
measurement of absorbance, a buffered-solution of HP-b-CD, of the same concentration as
in the studied solution, was always put as the reference. The average values of at least three
independent determinations of the absorbance were used for calculation of the concen-
trations of the particular acyclovir derivatives.
2.3 Extraction Experiments
The equipment described above was also used for the determination of the 1-octanol-water
partition coefficients. The procedure was as follows:
– An aqueous solution at a concentration of one half of the solubility of the substance
examined was prepared.
– The solution was placed in an ampoule and an identical volume of 1-octanol was
added.
– The ampoule was placed in a thermostat.
– The measurement was continued for 2 days with continuous stirring.
– The initial concentration in the aqueous solution and the final concentration of the
substance after each measurement were determined by spectrophotometry.




where Coc and Cw are the molar concentrations of the solute in the 1-octanol and water
phases, respectively. The correctness of the Poc/w value of each compound was verified by
checking the mass balance of the starting amount of the substance and the total amount of
the substance partitioned between the two phases.
2.4 Molecular Mechanics and Molecular Dynamics Experiments
Calculations were performed with the OPLS force field using HyperChem 7.0 software.
Molecular mechanic and molecular dynamic simulations were made using the conjugate
gradient algorithm included in HyperChem 7.0 software with convergence criteria of
0.004 kJmol-1. For each complex energy optimization 100 cycles of molecular
mechanic and molecular dynamic calculations were performed. Then 10 optimized
structures of complexes with the lowest energy of complexation were taken and
average values of energy of complexation and surfaces of acyclovir derivative and
cyclodextrin were determined. Calculations were performed with b-cyclodextrin because
hydroxypropyl-b-cyclodextrin used in experiments doesn’t have an exactly defined
structure. Simulations started from crystallographic structures of b-cyclodextrin and
acyclovir derivatives taken from the Cambridge Data Base of crystallographic struc-
tures: b-cyclodextrin CCDC ID: BUVSEQ02 [27], and acyclovir derivatives CCDC
ID:QOGQOS [28].
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3 Results and Discussion
Acyclovir derivatives which are the subject of this work are potential drugs, so it is
necessary to know their solubility in aqueous solutions and partition coefficient between
water and 1-octanol, which mimics cell membrane. These factors have significant influence
on absorption of drugs by cells and therapeutic effects. Values of water and 1-octanol
solubility of tricyclic acyclovir derivatives are shown in Table 1. The acyclovir derivatives
can be split into two groups: one, those possessing alkyl or halogen substituents (com-
pounds 1–7), for which aqueous solubility is in the range of 10-2 to 10-3 moldm-3, and
the second, with an aromatic group (compounds 8–12) for which the solubility in aqueous
solutions is extremely low (10-4 to 10-5 moldm-3). Solubilities of the studied compounds
in 1-octanol shows the opposite tendency, the solubility is smaller for compounds 1–7,
substituted by alkyl or halogen group. Additionally, both solubility of compounds 1–12 in
water saturated with 1-octanol, and in 1-octanol saturated with water, were determined and
compared with the previous results. Compounds for which the aqueous solubility is higher
than the solubility in 1-octanol are less soluble if the water is saturated in 1-octanol and
more soluble in 1-octanol saturated with water. Solubilities of acyclovir derivatives with
aromatic groups, which are more soluble in 1-octanol than in water, are higher if water is
saturated with 1-octanol. These dependences are shown in Fig. 2. Similar dependences of
aqueous solubility of both groups of the studied compounds were observed at higher
temperatures 35 and 45 C. Aqueous solubilities of compounds 1–12 at different tem-
peratures are presented in Table 2 and Fig. 3.
Analysis of the results presented in Tables 1 and 2 indicates that very low aqueous
solubility of acyclovir derivatives substituted by aromatic groups, compounds with good
antiviral activity towards herpes viruses [15], which is a barrier for their use as drugs. On
the other hand, the studied compounds have higher solubility in 1-octanol and in water
saturated with 1-octanol than in pure water, which suggests that the drugs may have
good permeation properties. The main reason for the low solubility of tricyclic acyclovir
derivatives with aromatic groups in water is the high hydrophobicity of these substitu-
ents. Use of cyclodextrins, which can include aromatic groups into their cavity, may
Table 1 Solubility of compounds 1–12 in water (Cw), water saturated with 1-octanol (Cwoc), 1-octanol
(Coc), and 1-octanol saturated with water (Cocw) at 25 C












1 ACV 80.70 (±1.6) 74.40 (±1.5) 2.12 (±0.18) 3.53 (±0.04)
2 Br-ACV 10.30 (±0.8) 8.59 (±0.3) 4.43 (±0.27) 6.89 (±0.40)
3 GCV 123.0 (±1.0) 110.0 (±3.0) 1.66 (±0.06) 3.83 (±0.36)
4 TACV 30.70 (±0.6) 27.20 (±0.8) 1.40 (±0.03) 4.27 (±0.14)
5 6-Me-TACV 187.0 (±3.7) 131.0 (±2.0) 32.4 (±0.03) 35.9 (±0.71)
6 2-Br-6-Me-TACV 21.10 (±0.4) 10.51 (±0.05) 2.27 (±0.1) 8.58 (±0.25)
7 6-t-But-TACV 30.80 (±0.3) 37.80 (±1.1) 159.0 (±2.0) 99.20 (±4.9)
8 6-Ph-TACV 2.38 (±0.15) 3.34 (±0.32) 17.80 (±1.2) 15.91 (±0.27)
9 6-Ph-Ph-TACV 2.29 (±0.16) 5.83 (±0.01) 20.40 (±1.3) 18.10 (±0.70)
10 6-Br-Ph-TACV 3.64 (±0.18) 4.12 (±0.12) 7.80 (±0.08) 6.81 (±0.20)
11 6-Ph-O-Me-TACV 0.53 (±0.02) 1.35 (±0.1) 4.03 (±0.06) 3.74 (±0.07)
12 6-Napht-TACV 1.66 (± 0.05) 1.91 (±0.04) 7.25 (±0.32) 6.84 (±0.20)
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enhance the aqueous solubility of such compounds. For this purpose we used several
cyclodextrins and hydroxypropyl-b-cyclodextrin was chosen as being more efficient for
complexating the tricyclic acyclovir derivatives [20]. The investigations were performed,
for chosen compounds, in various cyclodextrin HP-b-CD, buffered solutions (pH = 5.5
and 7.0) at 25 and 37 C. Figure 4 shows the dependence of acyclovir derivative on
cyclodextrin concentration for three compounds TACV, 2-Br-6-Me-TaCV and 6-Phe
TACV. It was found that the aqueous solubility of the compounds increased linearly with
cyclodextrin concentration in the solutions and can be described by the following
equation:






















Fig. 2 Solubility of compounds 1–12 in water (Cw), water saturated with 1-octano(Cwoc), 1-octanol (Coc)
and 1-octanol saturated with water (Cocw)
Table 2 Aqueous solubility of compounds 1–12 at 25, 35, 45 C
Compound Cw 9 10
-4 (moldm-3)
25 C 35 C 45 C
1 ACV 80.70 (±1.6) 162.0 (±8.0) 197.0 (±4.0)
2 Br-ACV 10.30 (±0.8) 19.0 (±1.1) 24.9 (±1.2)
3 GCV 123.0 (±1.0) 218.0 (±2.0) 229.0 (±3.0)
4 TACV 30.70 (±0.6) 59.1 (±2.9) 67.5 (±3.3)
5 6-Me-TACV 187.0 (±3.7) 266.0 (±10) 324.0 (±12)
6 2-Br-6-Me-TACV 21.10 (±0.4) 23.6 (±0.5) 25.9 (±0.7)
7 6-t-But-TACV 30.80 (±0.3) 204.0 (±3.0) 319.0 (±5.0)
8 6-Ph-TACV 2.38 (±0.15) 5.17 (±0.26) 7.28 (±0.32)
9 6-Ph-Ph-TACV 2.29 (±0.16) 5.54 (±0.23) 6.58 (±0. 3)
10 6-Br-Ph-TACV 3.64 (±0.18) 8.98 (±0.27) 12.8 (±0.33)
11 6-Ph-O-Me-TACV 0.53 (±0.02) 1.44 (±0.07) 4.65 (±0.23)
12 6-Napht-TACV 1.66 (±0.05) 2.56 (±0.04) 2.65 (±0.03)
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Cs ¼ a þ bCCD ð2Þ
where Cs represents the concentration of acyclovir derivative and CCD the cyclodextrin
concentration.
One exception is acyclovir derivative 7 possessing a tert-butyl substituent (6-t-But-
TACV) where this dependence is not linear over the whole range of cyclodextrin con-
centrations, showing an An type of solubility diagram. Values of the correlation parameters
a and b for tricyclic acyclovir derivatives complexed by cyclodextrin are presented in
Table 3. The linearity of acyclovir derivative concentration versus cyclodextrin concen-
tration in solutions and slope of line being lower than unity suggest 1:1 stoichiometry of
acyclovir derivative—cyclodextrin complexes [29]. The stability constants of the inclusion
complexes between HP-b-CD and acyclovir derivatives have been calculated according to
























25 30 35 40 45 50























Fig. 3 Solubility of compounds 1–12 versus temperature
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TACV (4) + HP-β-CD




























2-Br-6-Me-TACV (6) + HP-β-CD






















6-Ph-TACV (8) + HP-β-CD
Fig. 4 Solubility of tricyclic acylovir derivatives in aqueous buffered solutions (pH = 5.5 and 7.0)
containing hydroxypropyl-b-cyclodextrin at 25 and 37 C
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K ¼ b
C0ð1  bÞ ð3Þ
where C0 is the solubility of the sample in solutions without cyclodextrin, obtained
by determination of saturated solution concentration of acyclovir derivative solutions.
The a coefficients in Eq. 2 is the same solubility as C0, but this value is calculated by the
linear regression method. These two values can differ, but in our study are very close to each
other.
Table 4 presents values of stability constants of cyclodextrin inclusion complexes and
enhancement of aqueous solubility connected with the presence of cyclodextrin in the
solutions. The highest values of stability constants and 3–7 fold enhancement of solubility
are observed for compounds possessing aromatic groups, which may be bound inside the
cyclodextrin cavity. 1H NMR measurements confirm these conclusions [19]. Comparison of
the solubilities of acyclovir derivative 11 (6-Ph-O-Me-TACV) in buffer solutions (pH = 5.5
and 7.0), buffer containing 2 9 10-2 moldm-3 HP-b-CD, buffer saturated with 1-octanol
and containing 2 9 10-2 moldm-3 HP-b-CD, and 1-octanol saturated with buffer indicates
that the highest concentrations of 6-Ph-O-Me-TACV are observed in 1-octanol and cyclo-
dextrin solutions (see Fig. 5 and Table 5). The low concentration of acyclovir derivative in
buffer saturated with 1-octanol and containing cyclodextrin is connected with complexation
of 1-octanol in the cyclodextrin cavity that prevents complexation of 6-Ph-O-Me-TACV.
This conclusion is important for possible pharmaceutical usage of these derivatives. Com-
plexation of such drugs by cyclodextrin enhances their aqueous solubility but in contact with
1-octanol, which mimics the cell membrane, the drug is easily released from the cyclodextrin
complex as a result of competitive complexation of 1-octanol. The values of partition
coefficient of these compounds in 1-octanol-water calculated from extraction experiments
indicate good permeability of tricyclic acyclovir derivatives substituted with aromatic
groups, so the released drug can penetrate the cell membrane.
Table 3 Values of the correlation parameters a and b (Eq. 2) determinated using results of solubility of
tricyclic acyclovir derivatives in buffered HP-b-CD solutions
Compound t (C) pH = 5.5 pH = 7.0
a b a b
4 TACV 25 2.64 9 10-3 1.98 9 10-2 2.48 9 10-3 2.05 9 10-2
37 5.15 9 10-3 2.72 9 10-2 4.79 9 10-3 2.56 9 10-2
6 2-Br-6-Me-TACV 25 1.18 9 10-3 2.66 9 10-2 1.03 9 10-3 2.57 9 10-2
37 2.35 9 10-3 5.94 9 10-2 2.01 9 10-3 3.23 9 10-2
7 6-t-But-TACV 25 – – – –
37 – – – –
8 6-Ph-TACV 25 1.86 9 10-4 2.22 9 10-2 2.50 9 10-4 2.60 9 10-2
37 3.27 9 10-4 3.57 9 10-2 3.36 9 10-4 3.60 9 10-2
9 6-Ph–Ph-TACV 25 2.18 9 10-4 2.12 9 10-2 2.65 9 10-4 2.84 9 10-2
37 5.03 9 10-4 2.98 9 10-2 5.95 9 10-4 3. 89 9 10-2
11 6-Ph-O-Me-TACV 25 5.23 9 10-5 1.00 9 10-2 5.68 9 10-5 1.06 9 10-2
37 9.95 9 10-5 1.41 9 10-2 1.37 9 10-4 1.30 9 10-2
12 6-Napht-TACV 25 2.99 9 10-5 0.88 9 10-2 3.05 9 10-5 0.94 9 10-2
37 3.37 9 10-5 0.93 9 10-2 4.29 9 10-5 1.29 9 10-2
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Table 4 Stability constants of hydroxypropyl-b-complexes with tricyclic acyclovir derivatives and relative
enhancement of aqueous solubility, Cs/Co, of the derivatives in cyclodextrin buffered solutions at pH = 5.5
and 7.0 and two temperatures 25 and 37 C. The concentration of cyclodextrin is 2 9 10-2 (moldm-3)
Compound pH = 5.5 pH = 7
Ks (dmmol-1) Cs/Co Ks (dmmol-1) Cs/Co
25 C 37 C 25 C 37 C 25 C 37 C 25 C 37 C
4 TACV 8.0 (±1) 6.0 (±1) 1.11 1.1 8.0 (±1) 6.0 (±1) 1.1 1.1
6 2-Br-6-Me-TACV 27 (±2) 26 (±2) 1.4 1.5 26 (±2) 17 (±1) 1.5 1.3
7 6-t-But-TACV – – 1.5 1.6 – – 1.2 1.3
8 6-Ph-TACV 122 (±2) 113 (±10) 3.3 3.0 107 (±8) 105 (±6) 3.1 3.0
9 6-Ph-Ph-TACV 100 (±8) 61 (±5) 2.8 2.1 110 (±6) 68 (±4) 3.0 2.3
11 6-Ph-O-Me-TACV 213 (±6) 144 (±5) 5.1 3.8 189 (±6) 96 (±4) 4.8 2.9








































































Fig. 5 Comparison of solubility
of compound 11 (6-Ph-O-Me-
TACV) in buffered aqueous
solutions at pH = 5.5 (A) and 7.0
(B) (a), the same buffered
solutions containing
2 9 10-2 (moldm-3) HP-b-CD
(b), buffered solutions saturated
with 1-octanol (c) and containing
2 9 10-2 (moldm-3) HP-b-CD
(d), and in 1-octanol saturated
with buffer (e)
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The 1-octanol–water partition coefficients, for all compounds, are presented in Fig. 6
and Table 6. Table 6 contains, for comparison, values of the ratios: solubility in 1-octanol
and in water (Coc/Cw) as well as solubility in water saturated with 1-octanol and in
1-octanol saturated with water (Cocw/Cwoc). The partition coefficients have the same
sequence as the solubilities in 1-octanol, higher values were observed for compounds with
aromatic groups (see Fig. 7). The same tendency were observed for the Cocw/Cwoc ratio,
which may be used to envisage permeation possibilities of potential drugs if extraction
experiments are not performed. Enhancement of the aqueous solubility of acyclovir
derivatives can be treated as a first step for further study in preparation of new drugs
containing these compounds.
In order to know possible structures of the cyclodextrin complexes with tricyclic
acyclovir, we performed a series of molecular mechanics and molecular dynamics cal-
culations. Because of the lack of a well defined structure of hydroxypropyl-b-cyclodextrin,











Fig. 6 Partition coefficient 1-octanol–water of compounds 1–12 at 25 C
Table 5 Comparison of the solubility of compound 11 (6-Ph-O-Me-TACV) in buffered aqueous solutions
at pH = 5.5 and 7.0, the same buffered solutions containing 2 9 10-2 (moldm-3) HP-b-CD, buffered
solutions saturated with 1-octanol and containing 2 9 10-2 (moldm-3) HP-b-CD, and in 1-octanol satu-
rated with buffer
Solution C6-Ph-O-Me-TACV 9 10
-5 (moldm-3)
pH = 5.5 pH = 7.0
25 C 37 C 25 C 37 C
Buffer 4.82 (±0.15) 9.94 (±0.1) 5.50 (±0.23) 13.6 (±0.31)
Buffer ? HP-b-CD 24.4 (±0.82) 37.4 (±1.1) 26.5 (±95) 39.1 (±91)
Buffer saturated with 1-octanol 7.42 (±0.05) 12.7 (±0.1) 5.87 (±0.18) 13.9 (±0.21)
Buffer saturated with 1-octanol ? HP-b-CD 4.03 (±0.12) 7.70 (±0.21) 4.03 (±0.2) 8.06 (±0.32)
1-Octanol saturated with buffer 47.3 (±0.5) 74.1 (±0.41) 48.5 (±1.1) 88.2 (±2.3)
J Solution Chem (2013) 42:866–881 877
123
b-cyclodextrin has been taken for the calculations. Calculations were performed assuming
vacuum surroundings. Based of them, the energy of complexation and surface changes of
cyclodextrin and acyclovir derivative molecules during complexation were determined.
Results of the calculations are presented in Table 7. Looking at the results it is seen that the
energy of complexation is connected with the stability constants of the complexes and
changes in surfaces with enhancement of aqueous solubility. They show how deeply the
hydrophobic group is included in the cyclodextrin cavity and why it cannot interact with
water in solutions. Optimized structures of b-cyclodextrin complexes with two acyclovir
derivatives TACV and 6-Ph-TACV are presented in Fig. 8.













Fig. 7 Comparison of 1-octanol-water partition coefficient (Poc/w) of compounds 1–12 with ratios of
solubility of these compounds in 1-octanol and water (Coc/Cw) or 1-octanol saturated with water, and water
saturated with 1-octanol (Cocw/Cwoc) at 25 C
Table 6 Partition coefficient 1-octanol–water (Poc/w) of compounds 1–12, and solubility ratios of these
compounds in 1-octanol and water (Coc/Cw), in 1-octanol saturated with water and water saturated with
1-octanol (Cocw/Cwoc)
Compound Poc/w Coc/Cw Cocw/Cwoc
1 ACV 0.036 (±0.001) 0.026 0.048
2 Br-ACV 0.544 (±0.09) 0.430 0.802
3 GCV 0.017 (±0.001) 0.013 0.035
4 TACV 0.138 (±0.001) 0.046 0.157
5 6-Me-TACV 0.205 (±0.005) 0.173 0.274
6 2-Br-6-Me-TACV 0.780 (±0.009) 0.108 0.816
7 6-t-But-TACV 4.13 (±0.04) 5.16 2.62
8 6-Ph-TACV 3.51 (±0.29) 7.48 4.76
9 6-Ph–Ph-TACV 3.10 (±0.08) 8.90 3.10
10 6-Br-Ph-TACV 3.54 (±0.17) 2.14 1.65
11 6-Ph-O-Me-TACV 2.43 (±0.22) 7.62 2.84
12 6-Napht-TACV 3.54 (±0.01) 4.37 3.58
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Fig. 8 Structures of optimized structures of b-cyclodextrin complexes with tricyclic acyclovir derivatives
TACV and 6-Ph-TACV. Side view (a) and upper view (b)
Table 7 Energy of complexation and changes of b-cyclodextrin, acyclovir derivatives and their inclusion
complex surfaces determinated by optimization of the complex structure using molecular mechanics and
molecular dynamics methods
Compound DEcom
a (kJmol-1) DScomb (A˚2) DSsc (A˚2) DSCDd (A˚2)
4 TACV -180.00 -377.2 278.9 179.8
6 2-Br-6-Me-TACV -173.42 -434.8 302.9 214.3
7 6-t-But-TACV -186.90 -517.9 342.4 243.0
8 6-Ph-TACV -184.36 -486.0 325.5 241.9
9 6-Ph-Ph-TACV -181.31 -512.3 338.6 261.7
11 6-Ph-O-Me-TACV -202.22 -491.1 345.0 253.1
12 6-Naft- TACV -209.91 -536.1 362.4 249.4
a DEcom ¼ Ecom  ðEs þ ECDÞ, DEcom—energy of complexation, Ecom—calculated energy of cyclodextrin
inclusion complex with acyclovir derivative, Es—calculated energy of acyclovir derivative molecule, ECD—
calculated energy of cyclodextrin molecule
b DScom ¼ Scom  ðSs þ SCDÞ, DScom—change of surfaces during complexation process, Scom—surface of
complex, Ss –surface of free acyclovir derivative molecule, SCD—surface of free cyclodextrin molecule
c DSS ¼ Ss1  Ss2, DSs—difference between surfaces Ss1 and Ss2 of acyclovir derivative complexed by
cyclodextrin, where Ss2 is the surface of acyclowir derivative in the presence of cyclodextrin and Ss1 in the
absence of cyclodextrin
d Surfaces of cyclodextrin molecule in the complex, DSCD, DSCD1 and DSCD2, were calculated in the same
manner as surfaces of acyclovir derivatives
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4 Conclusions
The comparison of solubility of tricyclic acyclovir derivatives in water and buffered
solutions of HP-b-CD suggests that addition of cyclodextrin enhances the aqueous solu-
bility of the studied compounds by complexation of hydrophobic substituents in the
cyclodextrin cavity. Values of stability constants, which are in the range 10–300, give the
opportunity to easily release the compounds in the human body. Partition coefficients in the
range 2.5–4.1 for derivatives with an aromatic group suggest good absorption in body cells.
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